Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Teon Therapeutics

- PMLiVE

UK universities awarded over £58m by Cancer Research UK for clinician scientist training

The funding builds on the charity’s previous Clinical Academic Training Programme Award investment in 2019

- PMLiVE

ICR study shows how dormant breast cancer cells can be targeted to prevent relapse

Oestrogen receptor positive breast cancer accounts for up to 80% of all breast cancers cases

- PMLiVE

Cancer Research UK and Guardant collaborate to advance cancer detection and treatment

The partnership aims to accelerate the development of cancer drugs and diagnostics

- PMLiVE

Cancer Research UK calls on government to create ten-year cancer plan

The charity estimates that around 20,000 annual cancer deaths in the UK could be prevented by 2040

- PMLiVE

New genetic variants linked to prostate cancer in men with African ancestry

A dataset was compiled for the research containing DNA from over 944,000 men

- PMLiVE

Cancer Research UK and KWF Dutch Cancer Society partner for drug development

More than 390,000 people are diagnosed with cancer every year in the UK

- PMLiVE

Cancer Research UK partners with French cancer institute

Both organisations will support the global Cancer Grand Challenges initiative

- PMLiVE

ICR study finds way to determine efficacy of experimental breast cancer drugs

The findings could speed up the development of targeted therapies for breast cancer

- PMLiVE

New screening model shown to predict ten year breast cancer mortality risk

The risk-based screening model works to identify those at the highest risk of cancer

- PMLiVE

Long-term study reveals ‘ever-changing’ nature of lung cancer

The researchers hope the findings could help doctors to tailor treatments for individual patients

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

Precision medicine trial opens for patients with rare cancers

Rare cancers make up 22% of cancers that are diagnosed globally each year, more than any single type of cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links